HEADS UP RE: OSTEOSCREEN'S OSH-101

[elguapo]

I received the following in an email. Perhaps others who previously inquired about OSH-101 have received something similar.

"Look for a Press Release regarding our compound on 2-17-05. We'll try to post it to our website as soon as possible."

I don't want to get anybody's hopes up. I stopped visiting so frequently because I've just realized that nothing is going to come out TOMORROW. (And becaues I think Axon is somewhat of an a**h**, but that's a side note. Kidding.=)

Stay tuned, and good luck to all.

 

[Koala]

I received the following in an email. Perhaps others who previously inquired about OSH-101 have received something similar.

"Look for a Press Release regarding our compound on 2-17-05. We'll try to post it to our website as soon as possible."

I don't want to get anybody's hopes up. I stopped visiting so frequently because I've just realized that nothing is going to come out TOMORROW. (And becaues I think Axon is somewhat of an a**h**, but that's a side note. Kidding.=)

Stay tuned, and good luck to all.

Basically, they(OST) have products that are going to be licensed by Neosil...

That's the good news... from their point of view...

 

[Chipper]

reply

You dont understand. They have the money to go on with the trials of PS1, which means no more delays on waiting for funds anymore after partnering with new company.

 

[elguapo]

Damn right I don't understand! How do you guys know what's going on when the guy said the news won't be announced until tomorrow?

Can you send me a link? Or was this a story on CNN or something?

 

[Chipper]

reply

It's on hairsite.com go check it out.

 

[Brasileirao]

Dr. Gregory Mundy Joins Board of Directors

EMERYVILLE, Calif., Feb. 16 /PRNewswire/ -- Neosil, Inc., a privately held
specialty dermatology company, announced today that it completed in-licensing
of several hair growth products from OsteoScreen, Inc., a private company
focused on drug discovery for bone diseases. Terms of the agreement were not
disclosed.
"We are quite excited about the OsteoScreen products, one of which has
already been in an early-stage human clinical trial in Europe," said Eugene
Bauer, M.D., Neosil Chief Executive Officer. "This acquisition adds another
topical product to Neosil's existing pipeline of topical anti-bacterial and
anti-fungal programs and allows us to leverage our infrastructure to fully
exploit complementary areas of competency and expertise, such as microbiology
and formulations."
In connection with this in-licensing, Neosil announced that Gregory Mundy,
M.D., OsteoScreen founder and Chief Executive Officer, has been appointed to
its Board of Directors. A board-certified internist and endocrinologist, Dr.
Mundy is Professor of Cellular and Structural Biology and Director of
Orthopedic Research at the University of Texas Health Science Center, San
Antonio. He is internationally known for his work on osteoporosis and the
skeletal complications of cancer. The recipient of a prestigious M.E.R.I.T.
Award from the National Institutes of Health (NIH), Dr. Mundy has been an NIH-
funded investigator for the past 30 years and has served on both initial
review groups and on the Advisory Council of the National Institute of
Arthritis and Musculoskeletal and Skin Diseases. He is a member of numerous
honorific societies, including the American Society for Clinical Investigation
and the Association of American Physicians. He is the current President of
the International Bone & Mineral Society.
"I have known and worked with Greg Mundy for many years through our common
interests in connective tissue metabolism and through various NIH committees,"
commented Dr. Bauer. "He brings an extraordinary depth of knowledge and
breadth of experience to Neosil's Board in the cell biology of hair growth.
Greg will be an outstanding colleague on Neosil's Board."

About Neosil, Inc.
Neosil, Inc. is a privately held dermatology-focused pharmaceutical
company that was funded in November 2004 with a $32 million investment by MPM
Capital and Burrill & Company, following initial incubation funding by Shalon
Ventures, LP. In addition to Dr. Bauer and Dr. Mundy, Neosil's current Board
of Directors includes Nicholas J. Simon, III, General Partner, MPM Capital;
Ashley Dombkowski, Ph.D., Partner, MPM Capital; Ann F. Hanham, Ph.D., Managing
Director, Burrill & Company; and Teddy Shalon, Managing Director, Shalon
Ventures.

About OsteoScreen, Inc.
OsteoScreen Inc., a privately held biotechnology company located in San
Antonio, Texas, was founded in 1988 as a joint venture with the University of
Texas Health Science Center. The company focuses on the identification and
clinical development of new drugs for common diseases of bone. To date
OsteoScreen has raised over $35 million through corporate partnering,
milestone payments and licensing arrangements with major pharmaceutical
companies, including Rorer, Rhone-Poulenc Rorer, ZymoGenetics and Novo
Nordisk.


SOURCE Neosil, Inc.
Web Site: http://www.neosil.com


Read up FOCKERSS!!!!!!!!

 

[Buffboy]

So is this the famous press release?

 

[Brasileirao]

I'm not sure if its the 'official press' release since he mentioned it would happen on the 17th. But that is what I got, we will see if anything changes today...


Tony

 

[Buffboy]

Nothing came up during the day? What a scam...

 

[Brasileirao]

I e-mailed the lady from Neosil and she replied back quickly. I dont have the e-mail with me right now, its at work..forgot to e-mail it to my regular account. Any who, that post on the 16th was the press release....

Ill update this post once I have her response to my question.

Tony

 

[Guest]

Tony, did u get that email?

 

[Guest]

hey tony,
did you get that email?

 

[Brasileirao]

Yeah, I did get an e-mail back.....

Once I get to work Ill put it up...

Tony

 

[Brasileirao]

Ok guys, this is the response I got back...

Thank you for your inquiry regarding Neosil. The Company has not made
any announcements regarding the specifics of the compounds in its
pipeline or projected timing for commercialization of related products.
As is appropriate, such announcements will be made.
We appreciate your interest.

Ashley Dombkowski
Director, Neosil

Ashley (Ledbetter) Dombkowski, Ph.D.
Partner
MPM Capital
601 Gateway Boulevard, Suite 350
South San Francisco, CA 94080
Direct: (650) 553-3312
General: (650) 553-3300
Fax: (650) 553-3301
[email protected]

So I guess nothing new to report I will post anything else I receive in the future.

Tony Montana

 

[GoticGirl]

What about PS1?!?! :shock:

 

[thin=depressed]

For all we know it may perform like minoxidil which is far from a cure. But perhaps a regimen including min/adenosine/ps1 will be awesome.

 

[Bismarck]

For all we know it may perform like minoxidil which is far from a cure. But perhaps a regimen including min/adenosine/ps1 will be awesome.

??????????????????????????????????????????????????????????????????????

 

[Fallout Boy]

whatever happend to this product??? is it a lost cause or what?

 

[thin=depressed]

bark,bark,bark

 

[thin=depressed]

For all we know it may perform like minoxidil which is far from a cure. But perhaps a regimen including min/adenosine/ps1 will be awesome.

??????????????????????????????????????????????????????????????????????

Wait, O.K just checking above to confirm that I was in the right forum which is EXPERIMENTAL forum and not the 'how to be pompus' forum. :roll: